Characteristic | Identification Cohort (n = 20) | Confirmation Cohort (n = 47) | ||||
---|---|---|---|---|---|---|
HBsAg clearance | Non-HBsAg clearance | p | HBsAg clearance | Non-HBsAg clearance | p | |
No. | 10 | 10 | – | 17 | 30 | – |
Male sex, No.(%) | 9 (90%) | 7 (70%) | 0.582 | 15 (88%) | 24 (80%) | 0.692 |
aAge, y | 29 ± 8.9 | 46.4 ± 6.8 | 0.0001*** | 39 ± 7.7 | 38.7 ± 9.3 | 0.921 |
History of NAs | – | – | – | – | – | – |
Yes | 6 | 7 | 1 | 10 | 22 | 0.305 |
No | 4 | 3 | – | 7 | 8 | – |
Combination of NAs | – | – | – | – | – | – |
Yes | 4 | 4 | 1 | 5 | 8 | 0.84 |
No | 6 | 6 | 12 | 22 | ||
cHBV DNA, IU/ml | – | – | – | – | – | – |
undetectable (< 500) | 7 | 9 | 0.582 | 16 | 23 | 0.228 |
500~ 1000 | 3 | 1 | – | 1 | 7 | – |
bHBsAg at baseline, IU/ml | 186.09 (29.31–724.35) | 184.28 (62.75–536.69) | 1 | 116.54 (33.36–195.26) | 504.36 (156.35–875.49) | 0.01 |
< 500, No. | 7 | 7 | 0.549$ | 14 | 15 | 0.09$ |
500~ 1000, No. | 2 | 3 | – | 2 | 10 | – |
1000~ 1500, No. | 1 | 0 | – | 1 | 5 | – |
aALT baseline level, IU/ml | 36.4 ± 17.83 | 30.69 ± 9.9 | 0.388 | 31.51 ± 14.0 | 37.21 ± 30.65 | 0.474 |
aWBC,× 1012 | 6.12 ± 1.43 | 6.08 ± 1.37 | 0.951 | 5.98 ± 1.70 | 5.37 ± 1.28 | 0.176 |
Treatment outcome | – | – | – | – | – | – |
bPEG-IFN treatment course, w | 62.5 (49.8–70.8) | 49.5 (39.3–59.5) | 0.89 | 68 (48–72) | 71 (48–72.75) | 0.789 |
bHBsAg at EOT, IU/ml | 0.01 (0–0.014) | 228.3 (11.80–387.92) | 1.53E-4*** | 0 (0–0.01) | 20.86 (2.6–154.47) | 1.5783E-8*** |
Follow-up weeks | 56.3 (33.3–93.8) | 45.6 (32.4–80) | 0.241 | 25.6 (19.1–37.7) | 23.6 (14.3–39.1) | 0.542 |
bHBsAg at follow-up, IU/ml | 0.015 (0–0.02) | 184.26 (38.45–380.22) | 1.44E-4*** | 0 (0–0.02) | 28.11 (4.94–289.45) | 1.637E-8*** |